Author Archives: admin


Your Face May Have Been Shaped by Pressure in The Womb, Study Finds – ScienceAlert

Embryonic stem cells that play a critical role in determining our facial features during development can be hindered from growing when placed under increased pressure.

An international team of researchers took a look at the growth of mouse and frog embryos, as well as human embryoids (clusters of embryonic cells developed in the lab) to better understand how some cells tell others how to grow and differentiate.

They noticed that when an increase in hydrostatic pressure was applied externally to the embryo or embryoid, important cell signaling pathways in neural crest cells were disrupted.

The findings imply tissue development could be affected at crucial moments in an animal's development, placing them at risk of craniofacial malformations. These abnormalities are thought to be caused by a mix of genetic and environmental factors, including nutrient supply.

"Our findings suggest that facial malformations could be influenced not only by genetics but by physical cues in the womb such as pressure," says neurobiologist Roberto Mayor from University College London (UCL).

In what's known as embryonic induction, cells are sent along different biological paths during development by chemical signals from other nearby tissues. Scientists know about some, but not all, of the triggers that determine how stem cells interpret these cues.

In particular, the analysis looked at a fluid-filled cavity called the blastocoel, close to where the neural crest develops. Pressure on the blastocoel was shown to decrease the activity of a protein called Yap, which in turn impairs a group of signaling molecules known as Wnt, which are responsible for telling the neural crest how to develop.

While the study didn't investigate the causes of increased pressures inside the human uterus, the findings provide insight into mechanical influences on the embryo where most studies tend to focus on the influence of biochemical factors instead.

"When an organism is experiencing a change in pressure, all the cells including the embryo inside the mother are able to sense it," says Mayor.

The research gives scientists an important step forward in their understanding of how humans (and other vertebrates) form, right down to the individual molecules and signals involved in the earliest stages of development.

While it's clear pressure can cause neural crest signaling to become less efficient, it remains to be seen how particular changes in the uterine environment might give rise to specific outcomes in a developing human child.

"Our work shows that embryos are sensitive to pressure, but we do not know how sensitive they are," says Mayor. "For instance, will a change in the pressure inside the uterus be able to affect the embryo?"

"This will require further research to understand how changes inside the body as well as in environmental pressure might influence human embryo development."

The research has been published in Nature Cell Biology.

The rest is here:
Your Face May Have Been Shaped by Pressure in The Womb, Study Finds - ScienceAlert

Sketchy stem-cell treatments in Mexico led to drug-resistant infections – Livescience.com

Three people who traveled to Mexico for stem-cell injections that are not approved in the U.S. contracted difficult-to-treat, drug-resistant infections, a Morbidity and Mortality Weekly Report (MMWR) from the Centers for Disease Control and Prevention warned Thursday (May 9).

The infections were caused by Mycobacterium abscessus, a bacterium that's distantly related to the ones behind tuberculosis and leprosy. The microbe commonly lurks in soil, water and dust, and it's known to sometimes contaminate medications and medical devices and thus cause infections in health care settings.

Symptoms can include boils and pus-filled bubbles, in the case of skin infections, as well as fever, chills and muscle aches, when soft-tissue infections occur. Sometimes, the bacteria can invade the bloodstream. Treating the infection involves removing infected tissues and draining pus from the body, as well as giving antibiotics for a prolonged period.

For a given patient, doctors may have to test different drugs against samples of bacteria from their body, in order to find the most lethal combination against the drug-resistant bug.

All three patients who got stem-cell injections in Mexico underwent the procedures in 2022, and as of March 2024, they were still being treated for M. abscessus infection in U.S. hospitals, according to the MMWR.

Related: Dangerous 'superbugs' are a growing threat, and antibiotics can't stop their rise. What can?

"Providers and public health agencies need to be aware of the risk for M. abscessus infections from stem cell treatments for indications not approved by the Food and Drug Administration and maintain vigilance for similar cases," the report's authors wrote. "They also are advised to provide guidance for persons considering medical tourism."

Get the worlds most fascinating discoveries delivered straight to your inbox.

The only stem-cell products currently approved in the U.S. contain precursors to different cells in the blood, and they're cleared to treat disorders that affect the production of blood.

The first of the three cases involved a Colorado woman in her 30s, who in October 2022 had traveled to Baja California to get stem-cell injections in the tissues that surround the brain and spinal cord.

The injections were reportedly intended to treat the autoimmune disease multiple sclerosis, for which there are no approved stem-cell treatments in the U.S. After the injections, she developed headaches and fever, and at a hospital in the U.S., the fluid around her brain and spinal cord tested positive for M. abscessus. This indicated she had a serious infection called bacterial meningitis.

Two similar cases involved men in their 60s one from Arizona and one from Colorado. The Arizona man had developed an infection in his elbow after traveling to Baja California for treatment of psoriatic arthritis. He was treated at a different clinic than the Colorado woman was, and the clinics were 167 miles (269 kilometers) apart.

The Colorado man, meanwhile, had traveled to Guadalajara, Mexico, for treatment of osteoarthritis in his knees and then developed infections in both knees. The use of stem-cell injections for multiple sclerosis and arthritis are unproven, as potential stem-cell therapies for these conditions are still being investigated.

While treating the patients, a U.S. hospital obtained samples of the M. abscessus bacteria from the Colorado woman and Arizona man; samples from the Colorado man still need to be closely assessed, but they've been confirmed to be M. abscessus.

Genetic analyses revealed that the two patients' samples were a near-perfect match. Therefore, the investigators "suspect a common infected source" for these two patients, meaning the same products or equipment may have been contaminated in both cases.

However, authorities "attempted to contact clinics that performed the stem cell injections, but received no response," the MMWR notes, and "attempts to identify the product or gather details about its administration have been unsuccessful to date." Authorities in the U.S. and Mexico are continuing to investigate the three known cases and are looking for additional ones.

Medical tourism has been tied to M. abscessus infections in the past. For example, a Canadian man who underwent a hair transplant in Panama developed such an infection on his scalp. So these superbug infections can arise after both cosmetic procedures and therapies intended to treat disease.

This article is for informational purposes only and is not meant to offer medical advice.

Ever wonder why some people build muscle more easily than others or why freckles come out in the sun? Send us your questions about how the human body works to community@livescience.com with the subject line "Health Desk Q," and you may see your question answered on the website!

Read the original:
Sketchy stem-cell treatments in Mexico led to drug-resistant infections - Livescience.com

Mikkael Lamoca receives Fulbright scholarship to complete cutting-edge STEM cell research – Rochester Institute of Technology

Conducting hands-on research was a hallmark of the time Mikkael Lamoca 24 (biomedical engineering), 24 MS (science, technology, and public policy) spent at RIT. A Fulbright award presents him a new opportunity to conduct cutting-edge research at one of the top universities in Asia.

Lamocas award will fund a 10-month research experience in the BioIonic Currents Electromagnetic Pulsing Systems (BICEPS) Laboratory at the National University of Singapore. He is one of a record six Fulbright U.S. Student awardees this year from RIT.

His research focuses on age-related neurodegeneration, which can be seen in Alzheimers disease, dementia, and other conditions. There is previous research regarding how STEM cell injections can help with these conditions, but, according to Lamoca, there is contradicting information and evidence which indicates this method may not be the best approach.

Instead, Lamoca will explore how magnetic stimulation can induce secretome production to achieve therapeutic neuroprotective effects.

One of the biggest reasons I wanted to work with this lab is that I would be the first person there to do this type of research on neuroprotection, and that I would have access to work with the labs patented technology. This lab established all of the processes for magnetically induced secretome production, so Im going to use their methods to see if it can be applied to neuroprotection efforts, said Lamoca.

When looking for co-op opportunities during his second year at RIT, Lamoca, from Santa Clara, Calif., was introduced to RITs Tissue Regeneration and Mechanobiology Laboratory, led by Professor Karin Wuertz-Kozak. His friend, Iskender Mambertkadyrov 24 (biomedical engineering), 24 MS (science, technology, and public policy), recommended that he inquire about available opportunities in the lab and Lamoca flourished from there.

Coming into my first year, I didnt know much about research. My co-op with Professor Wuertz-Kozak was the first time I really started to dive into it. She was my first mentor. Working in her lab is where my love of research started, and Ive been interested in doing more ever since, said Lamoca.

After completing his 10-month tenure at the BICEPS laboratory in Singapore, Lamoca hopes to continue his graduate education by earning a Doctorate of Medicine and of Philosophy (MD-Ph.D.) so can practice medicine while conducting research.

Continue reading here:
Mikkael Lamoca receives Fulbright scholarship to complete cutting-edge STEM cell research - Rochester Institute of Technology

Novel technology positions ‘off-the-shelf’ cancer immunotherapy for the clinic – UCLA Newsroom

Immunotherapies have revolutionized cancer treatment by harnessing the bodys own immune system to attack cancer cells and halt tumor growth. However, these therapies often need to be tailored to each individual patient, slowing down the treatment process and resulting in a hefty price tag that could soar well into the hundreds of thousands of dollars per patient.

To tackle these limitations, UCLA researchers have developed a new, clinically guided method to engineer more powerful immune cells called invariant natural killer T cells, or iNKT cells, that can be used for an off-the-shelf cancer immunotherapy in which immune cells from a single cord-blood donor can be used to treat multiple patients.

This novel technology, described in a study published by Nature Biotechnology, marks a major step toward enabling the mass production of cell therapies like CAR-T cell therapy, making these life-saving treatments more affordable and accessible to a broader range of patients.

The studys senior author,Lili Yang, a professor of microbiology, immunology and molecular genetics and a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA and of theUCLA Health Jonsson Comprehensive Cancer Center, breaks down why this new system is poised to finally help a universal cell product advance to a clinical trial.

What are the key developments of this paper?

In 2021, our team reported amethod for producing large numbers of iNKT cellsusing blood stem cells. That system required the use of three-dimensional thymic organoids and supportive cells, which posed both a manufacturing and regulatory challenge that prevented that method from ever reaching clinical application.

Now, weve developed a technology that can produce large quantities of iNKT cells from blood stem cells in a feeder-free and serum-free manner. This update to the method eliminates the previous hurdles, bringing us closer than ever to delivering an off-the-shelf cancer immunotherapy to patients.

How did you reach these findings?

UCLA

Clockwise from top left: Senior author Lili Yang and co-first authors Yan-Ruide Li, Jiaji Yu and Yang Zhou.

Our team isolated the blood stem cells, which can self-replicate and produce all kinds of blood and immune cells, from 15 donor cord-blood samples representing diverse genetic backgrounds. We then genetically engineered each of those cells to develop into useful iNKT cells and estimate that one cord-blood donation can produce between 1,000 to 10,000 doses of a therapy making the system really well suited to create an off-the-shelf immunotherapy.

Next, our team equipped the iNKT cells with chimeric antigen receptors, or CARs, molecules that enable immune cells to recognize and kill a specific type of cancer, to target seven cancers that included both blood cancers and solid tumors. The CAR-iNKT cells showed a robust anti-tumor efficacy against all seven cancers, indicating their promising potential for treating a wide spectrum of cancers. Then in a multiple myeloma model, we demonstrated the CAR-iNKT cells ability to halt tumor growth without causing complications that can sometimes occur when donor cells are transplanted into a patient.

Why are iNKT cells so special?

We consider invariant natural killer T cells to be the special forces of the immune cells because theyre stronger and faster than conventional T cells and can attack tumors using multiple weapons. Its ideal to use iNKT cells as an off-the-self cancer immunotherapy because they dont carry the risk of graft-versus-host disease, a condition in which transplanted cells attack the recipients body and the reason most cell-based immunotherapies have to be created on a patient-specific basis.

What excites you about these developments?

No off-the-shelf cell therapy has ever been approved by the U.S. Food and Drug Administration. With this new technology, not only have we shown a high output of iNKT cells, but weve also proven that the CAR-equipped iNKT cells dont lose their tumor-fighting efficacy after being frozen and thawed, which is a key requirement for the widespread distribution of a universal cell product.

While CAR-T cell therapies have been a transformative treatment for certain blood cancers like leukemia and lymphoma, it has been challenging to develop a cancer immunotherapy for solid tumors. This is in part because solid tumors have an immunosuppressive tumor microenvironment, meaning the immune cell function is impaired in the environment. iNKT cells can change the tumor microenvironment by selectively and effectively depleting the most immunosuppressive cells in its surroundings giving them the unique opportunity to attack solid tumors. Were extremely excited that this technology has a potential broad application to target a range of blood cancers, solid tumors and other conditions such as autoimmune diseases.

Whats the biggest bottleneck in cancer immunotherapy?

The biggest bottleneck right now for immunotherapies, particularly cell therapies, is manufacturing. As of 2023, the FDA has approved six autologous CAR-T cell therapies with an average cost of around $300,000 per patient, per treatment. Using this novel technology to scale up iNKT cell production, theres a real possibility that the price per dose of immunotherapy can drop significantly to $5,000. By definition, an off-the-shelf product would be readily on hand in clinical settings, so my hope is that this new system will result in a reality where all patients who need the treatment will be able to receive it immediately.

What are the next steps in the study?

Our team is advancing this multiple myeloma model project into an IND-enabling study this year, which would result in a Phase 1, first-in-human clinical trial of this technology.

Since this flexible platform allows us to switch the CARs to target different cancers, our team has since adapted this same system to target ovarian cancer, one of the deadliest gynecologic cancers. This represents a big leap from targeting blood cancers to solid tumors, but were hopeful to bring this project to a clinical trial over the next couple of years.

Read the original:
Novel technology positions 'off-the-shelf' cancer immunotherapy for the clinic - UCLA Newsroom

How Exosome Therapy Gave Me the Skin of My Younger Self – Vogue

I never received compliments on my skin until beginning exosome therapy last fall. A few months prior, at the recommendation of Chioma Nnadiformer editor of Vogue.com and current head of editorial content at British VogueI took a consultation visit with practitioner Dr. Akis Ntonos, FNP, ND.

At the time, tackling hyperpigmentation was my main concern, so Ntonos emphasized that our course of action would include alleviating breakouts, balancing my skin's oil production, and reducing pore size. It all started with an in-office chemical peel, then a stem cell microneedling treatment. A few days after our first visit, he called to check in and ask a question: Would I like to participate in an exclusive skin study on skincare's next big ingredient, exosomes?

I didn't really know what exosomes were or how it could help me achieve my skin goals. I had so many questions. Exosomes, Ntonos tells me, are small vehicles released by all cells, including stem cells. In simple terms, exosomes are messengers that carry essential information and factors from one cell to another. By delivering these nanoparticles directly to the skin, one could receive better results. Per Ntonos, exosomes are preferred over actual stem cell applications because they are less contentious as they do not involve whole cells, mitigating the concerns of potential rejection or other complications.

Ntonos explains that exosomes are desirable in the aesthetic would because they enhance the skin's regenerative processes, which results in a more youthful appearance and better outcomes post-treatment. This improves skin quality and appearance, making them ideal for anti-aging and skin rejuvenation treatments. Wrinkles, skin laxity, uneven skin tone, and textural irregularities are all concerns exosomes target; it may also help prevent scarring, improve the appearance of old scars, and potentially treat inflammatory skin conditions. There are even ongoing studies that exosomes can improve hair restoration.

In 2020, Resilille discovered how to harvest many exosomes from a single umbilical cord per batch. Or Age Zero exosomes, as they call them, are derived from Wharton Jelly stem cells which are known for their therapeutic qualities; and, thus primed to achieve an improvement in skin texture, firmness, pore size, and radiance per Resilille CEO Erin Crowley. This innovation helps the ingredients be readily available for aesthetic treatments.

View post:
How Exosome Therapy Gave Me the Skin of My Younger Self - Vogue

Colorado patients among those infected after stem-cell treatments in Mexico – 9News.com KUSA

The treatments were given at clinics in the Mexico border state of Baja California, according to the CDC report issued Thursday.

MEXICO CITY, Mexico The U.S. Centers for Disease Control and Preventionissued a report Thursday about three cases of infections two of them in Colorado patients apparently linked to stem-cell treatments American patients received in Mexico.

The CDC issued the report Thursday on infections of Non-Tuberculous Mycobacteria (NTM), which it described as difficult-to-treat and intrinsically drug-resistant and rapidly growing.

All three patients, two of them from Colorado, remain in treatment. The infections were apparently acquired during stem-cell injections carried out at two clinics in the Mexican border state of Baja California, located 167 miles apart.

In the past, Americans and Mexicans have been infected apparently because some doctors in Mexico were taking multiple doses of anesthetics from a single vial due to shortages or other problems, though it was not clear whether that was a possible cause in the most recent outbreak reported Thursday.

The first case was reported in late 2022, in a woman who had embryonic stem-cell treatment in October 2022 for multiple sclerosis. The woman from Colorado was in her 30s, and experienced headaches and fevers consistent with meningitis.

In spring 2023, two male patients in their 60s one from Colorado and one from Arizona were found to have infections in their joints after receiving stem-cell treatments in Baja California for forms of arthritis. The Colorado man developed knee infections after receiving stem-cell injections in both knees in Guadalajara, Mexico.

The CDC report said vigilance for similar cases and guidance for persons considering medical tourism are advised.

In the past, local problems with the availability of morphine and fentanyl led some anesthesiologists in Mexico to acquire their own supplies, carry the vials around with them and administer multiple doses from a single vial to conserve their supply.

In 2022, anesthetics contaminated by those practices caused a meningitis outbreak in the northern state of Durango that killed about three dozen people, many of whom were pregnant women given epidurals. Several Americans died because of a similar outbreak after having surgery at clinics in the Mexican border city of Matamoros in 2023.

More 9NEWS health coverage:

SUGGESTED VIDEOS: Health

Visit link:
Colorado patients among those infected after stem-cell treatments in Mexico - 9News.com KUSA

Parkinson’s patient moves freely again after world-first implant of lab-grown cells into his brain – Euronews

Parkinsons patient Thomas Matsson was the first in the world to receive 7 million lab-grown brain cells in 2023. Today, he can smell and play sports.

Researchers at Lund University in Sweden have successfully implanted 7 million lab-grown brain cells into a patient to treat Parkinson's disease.

Swedish resident Thomas Matsson was the first in the world to test the method about a year ago.

Matsson was diagnosed with Parkinson's when he was 42. For the last 17 years, he felt like he was walking through a syrup, he says.

Mister P, the disease, would pull my neck one way when I was going the other, said Matsson.

Today, Matsson recognises smells again and plays sports.

The syrup is gone. Ive got my 7 million cells and they are starting to work now, said Matsson.

Ive reduced my medication for Parkinsons. Before, everything was slow and everything was difficult, he added.

Matsson says he is hitting golf shots that he hasnt been able to hit in 10 years.

I do long-distance skating, slalom, cross-country skiing, padel tennis, and, above all, golf, he said.

To be able to skate when youve had Parkinsons for 20 years, not many people do that I think. And then 28 days in Spain where I played 25 rounds in 28 days, you cant really do that when youre healthy most of the time. Something happened. Something very good.

Parkinsons disease is a neurodegenerative disorder that affects movement primarily due to the loss of cells that produce dopamine, which helps transmit signals that control movement and coordination as a neurotransmitter.

The cell therapy devised by researchers at Lund University involves exposing stem cells from fertilised eggs - called embryonic stem cells - to growth factors and signals they would normally receive during embryo development to direct them to become immature dopamine cells.

The cells are then implanted into a 4 mm area in the centre of the patient's brain, closest to the brain stem to replace the dopamine cells Parkinsons patients have lost.

After a few months, they start sending out nerve fibres and producing dopamine.

The vision is that it could be given as a one-time treatment and the hope is that the patients can reduce their medication, avoid side effects of the drug treatment and get a long-term good motor effect from the cells for life, Gesine Paul-Visse, a senior physician in neurology at Skne University Hospital and adjunct professor at Lund University, told Swedish broadcast SVT in 2023 when the first trials started.

Matsson did not feel well immediately when he woke up from the 13-hour procedure. He suffered a psychosis for 10 days.

Among other things, I escaped from the ward twice. The second time it was the police who drove me back. Its not something I want to experience again. Absolutely not, Matsson said.

Whether it was an effect of the long exposure to anaesthesia or whether it had to do with his brain adjusting to the new brain cells is unknown.

So far, five subjects have undergone surgery using the researchers' lab-grown cells.

Soon three additional patients will receive a double dose, with 14 million brain cells each.

Theres always a theoretical risk of tumours forming, which is likely to increase if you have a higher number of implanted brain cells, Paul-Visse said.

Then there is a risk of over-medication, that you produce too much dopamine in the brain. I think this risk is extremely low, she added.

If all goes well with the first eight patients, the research team will continue with larger studies in collaboration with a pharmaceutical company.

The interest from patients has been incredible. There are even patients living abroad who would have liked to move to Sweden to participate in this study. And we had to inform all patients that the recruitment for this study was closed, said Paul-Visse.

Matsson says he is 110 per cent certain that the research team will succeed.

I am absolutely convinced, 110 per cent! And I hope that these scientists will eventually get their just rewards, he added.

The hope is that the cultured cells will be available as a medicine worldwide in seven to ten years.

There is absolutely hope. Absolutely there is! said Paul-Visse as a message to people living with Parkinsons disease.

For more on this story, watch the video in the media player above.

See the original post:
Parkinson's patient moves freely again after world-first implant of lab-grown cells into his brain - Euronews

The transcription factor OCT6 promotes the dissolution of the nave pluripotent state by repressing Nanog and … – Nature.com

Oct6 is one of the earliest TFs induced during the exit from nave pluripotency

To shed light on the conversion of GRNs from nave to formative pluripotency, we initially focused on the TFs induced at early stages of differentiation, since they could be crucial to GRN restructuring. Based on a thorough study performed by Yang and collaborators18, we identified TFs that were upregulated in the first 6h of the transition and remained highly expressed at 48h (Fig. S1A). This preliminary analysis revealed known facilitators of formative pluripotency, such as Otx2, Foxd3 and c-Myc15,16,19. Other TFs that exhibited this trend include the retinoic acid receptors Rarg and Rxrg, as well as Myrf, Ar, and Aff3. Interestingly, among these early-induced genes, Oct6 (also known as Pou3f1) was the one that displayed the most important induction when comparing mESCs vs. 48h EpiLCs, and it was significantly upregulated only 2h after the onset of differentiation (Fig.1A). In contrast, other formative markers such as Fgf5, Otx2, and Dnmt3A were upregulated at later time points. The rapid induction of Oct6 transcription was accompanied by a significant decrease of the nave TF Klf4 expression at 2h, whereas other nave TFs such as Nanog, Esrrb, and Tbx3 were downregulated at later time points. Quantitative immunofluorescence showed that OCT6 was not detected in nave pluripotent ground state conditions and that its levels increased gradually as cells entered formative pluripotency, with all cells expressing this TF at 48h of differentiation (Fig.1B, Fig. S1B). In light of these results, we decided to assess the role of Oct6 in the dissolution of nave pluripotency.

Loss of Oct6 affects the transition to formative pluripotency. (A) RT-qPCR analysis of nave and formative pluripotency markers during the first hours of EpiLC differentiation. Results are presented as meanSEM for three independent replicates. Different letters indicate significant differences between time points (p<0.05). (B) Quantification of nuclear OCT6 during EpiLC induction. The violin plot shows the distribution of OCT6 nuclear intensity for each timepoint and the circles show the mean fluorescence for individual cells. (C) Diagram of Oct6 genomic locus showing the sgRNA binding region for CRISPR/Cas9 mediated KO generation. (D) Representative immunoblot showing OCT6 depletion in Oct6 KO EpiLCs. GAPDH was used as a loading control. (E) Representative immunofluorescence of OCT6 in WT and KO 48h EpiLCs. DAPI was used as a nuclear stain. Scale bar: 50m. (F) Morphological differences between WT and Oct6 KO cells induced to differentiate to EpiLCs. Brightfield micrographs of WT and Oct6 KO EpiLCs. Scale bar: 50m. (G) Left. Representative images of DAPI stained nuclei of WT and Oct6 KO EpiLCs. Right. Distribution of the distances to the nearest neighbor cells for all nuclei in the representative images (see Materials and Methods). (H) Heatmap of differentially expressed genes between WT and Oct6 KO EpiLCs as obtained from Deseq2 analysis. (I) Examples of DE gene expression for nave pluripotency genes (top) and formative genes (bottom) from the RNA-seq results. (J) RT-qPCR analysis of Nanog in WT and Oct6 KO EpiLCs. Results are as presented as meanSEM for three independent replicates. (K) Representative immunofluorescence of NANOG in WT and Oct6 KO EpiLCs. Scale bar: 100m. (L) Flow cytometry analysis of Nanog expression showing higher expression in Oct6 KO cells compared to WT EpiLCs.

We then conducted an analysis of the Oct6 promoter by examining previously published ChIP-seq experiments to identify potential cis-regulatory elements (CRE) and likely regulators influencing Oct6 expression14,16,18,20,21,22. We discovered two CREs located 10 and 12kb upstream of the transcription start site, which we refer to as CRE#1 and CRE#2, respectively (Fig. S2). In mESCs maintained in 2i+LIF, the TFs OCT4, OTX2, NANOG, and ESRRB bind only to CRE#2 and not to CRE#1. Interestingly, EpiLCs presented a reorganization of OCT4 and OTX2 binding, with their occupancy extended to CRE#1. Moreover, this regulatory element exhibited an increased signal of the active enhancer marks H3K27ac and H3K4me1, along with open chromatin detected by ATAC-seq. These analyses collectively suggest that CRE#2 acts as a regulatory sequence specific to nave pluripotency, potentially involved in repressing Oct6 expression, while CRE#1 may function as an enhancer specific to EpiLCs.

To directly assess the role of Oct6 in the transition to EpiLCs, we generated an Oct6 knockout line (Oct6-KO) using CRISPR/Cas9 in 46C mESCs (Fig.1C, Fig. S3A). Western blot and immunofluorescence analysis confirmed the lack of expression of OCT6 protein after induction to EpiLCs (Fig.1D,E). Importantly, KO cells cultured in ground state conditions did not show any changes in morphology or the expression of the pluripotency transcription factor Nanog (Fig. S3B,C).

Oct6 has been previously reported as a key player in neural progenitor cell (NPC) differentiation. We thus evaluated the ability of the Oct6-KO cells to differentiate to the neural lineage by taking advantage of 46C mESCs line, that expresses GFP under the control of the neural marker Sox1. As expected, Oct6-KO cells produced significantly lower rates of SOX1-GFP+cells than WT 46C cells after 6days of differentiation (~60% vs.~90% SOX1-GFP+cells, respectively) (Fig. S3D). These data are consistent with Oct6 promoting neural induction, although its expression is not fundamental for the differentiation of NPCs.

We then addressed if Oct6-KO cells were affected in their differentiation capacity to EpiLCs. The transition from nave to formative pluripotency is accompanied by important morphological changes. mESCs in the nave ground state grow as tightly packed colonies with a dome shape. Upon EpiLC induction, cells quickly undergo a morphological conversion that includes flattening, diminished cellcell interactions, and the formation of cellular protrusions14,23. Interestingly, we noticed that upon differentiation, Oct6-KO cells exhibited a more compact morphology with considerably fewer protrusions compared to parental WT cells (Fig.1F). Indeed, quantification of the distribution of distances to each cells nearest neighbor both for WT and KO EpiLCs confirmed that Oct6-KO cells were more tightly packed and did not show colony-detached cells as in the case of WT EpiLCs (Fig.1G). Thus, the absence of Oct6 impairs the phenotypic changes observed as mESCs exit nave pluripotency.

To further assess the role of Oct6 during differentiation we performed an RNA sequencing (RNA-seq) experiment on WT and Oct6-KO EpiLCs. A total of 292 genes were differentially expressed (DE) with at least 1 log twofold change (Fig.1H, Table S1). Functional annotation analysis of the DE genes with Gene Ontology (GO) revealed significant enrichment for the biological process term regulation of cell motility (GO:2000145) and the cellular component terms plasma membrane bounded cell projection (GO:0120025) and cell leading edge (GO:0031252), in agreement with the phenotypic effects previously observed (Table S2). Importantly, the GO term cell differentiation (GO:0030154) was also highly enriched, suggesting that KO EpiLCs may display alterations in their differentiation capacity. Among the DE genes, we found that key TFs associated with nave pluripotency such as Esrrb, Klf2, Nr5a2, Dppa2, Tdh, Zic3, and Prdm14 showed higher expression levels in KO cells compared to WT EpiLCs (Fig.1I, Fig. S3E). Interestingly, although not detected in the RNA-seq data due to the stringency of the analysis, assessment of the master pluripotency regulator Nanog also showed a slight but significant upregulation in KO EpiLCs, both at the mRNA and protein level (Fig.1JL). On the other hand, genes associated with the transition to formative pluripotency or neural differentiation such as Zic2, Sox1, Nestin, Foxp1, and Hoxa124 were less expressed in KO EpiLCs. Supporting the role of Oct6 in the changes in cell morphology, we also observed differences in genes associated with cell attachment such as Vimentin, E-Cadherin, N-Cadherin and Claudins 5, 6, 7 and 9 (Fig. S3E,F). In summary, our results indicate that the absence of Oct6 impairs the correct acquisition of the GRN associated with formative pluripotency.

We next intended to assess the genome-wide binding of OCT6 in EpiLCs. However, there are currently no suitable Oct6 antibodies for ChIP (see the Discussion). Therefore, we analyzed previously published data, where Matsuda et al. evaluated OCT6 binding in epiblast stem cells (EpiSCs) by overexpressing a tagged version of Oct625. Although EpiLCs and EpiSCs represent different developmental stages of post-implantation epiblast development, we reasoned that these data could be useful to infer which of the DE genes in our RNA-seq experiment could be direct targets of OCT6. Indeed, among the 292 DE genes detected in our RNA-seq, 114 were associated with OCT6 ChIP binding peaks in EpiSCs (Fig. S4A). This number was almost three times higher than the~40 genes that would be expected out of chance, as evaluated by a bootstrap analysis. Interestingly, among the DE genes of our RNA-seq that contained OCT6 peaks in EpiSCs we found the nave pluripotency expressed genes Dppa2, Prdm14, Nr5a2, and Vim and the EpiLCs induced genes Zic2, Zic3, Sox1, Nes, and Foxp1 (Fig. S4B). Overall, this analysis validated our RNA-seq results and identified genes that are potentially regulated by Oct6 at the transcriptional level by direct binding to their loci.

To further study the role of Oct6 in the transition from nave to formative pluripotency, we analyzed the effect of its premature expression in the pluripotent ground state. To that end, we engineered a new cell line where KO cells were complemented with a construct that allows the doxycycline (Dox) inducible expression of an HA-tagged version of OCT6, together with the fluorescent protein mCherry via a self-cleaving peptide (Fig.2A). As expected, the addition of Dox induced the expression of the Oct6 and mCherry transgenes, while allowing the in vivo observation of red fluorescence in OCT6 overexpressing cells (Fig.2B). Quantitative immunofluorescence confirmed that mCherry signal was a good proxy of OCT6 expression since their levels were highly and linearly correlated throughout several orders of magnitude (Fig.2C). Importantly, induction of transgenic OCT6 expression in differentiating KO cells rescued the morphological effect observed previously, as seen by the reappearance of diminished cellcell interactions and cell protrusions (Fig.2D).

Overexpression of Oct6 in undifferentiated cells promotes morphological and transcriptional changes associated with formative pluripotency. (A) Diagram of the Oct6-P2A-mCherry overexpressing construct and the experimental design. (B) Treatment with Dox in 2i+LIF medium induces the expression of mCherry and a morphological transformation reminiscent of formative cells. Scale bar: 200m. (C) The plot shows the linear correlation of mean nuclear intensity fluorescence of mCherry and OCT6 obtained from OCT6 immunostaining of Dox treated cells. Each circle shows the data of one individual nucleus. (D) Overexpression of Oct6 in KO EpiLCs rescues the morphological differences observed between WT and KO EpiLCs. Scale bar: 50m. (E) RT-qPCR analysis of nave and formative markers upon Dox treatment. Results are as presented as meanSEM for three independent replicates. (F) Representative immunofluorescence showing how Dox treatment induces the repression of NANOG in Oct6-P2A-mCherry expressing cells. Scale bar: 100m. (G) Quantification of immunofluorescence experiments of mCherry and NANOG in untreated or 24, 48, and 72h Dox treated cells in 2i+LIF medium. The violin plots show the distribution of mCherry or NANOG nuclear intensity for each time point. The circles show the mean fluorescence for individual cells. (H) The plot shows the correlation between Oct6-P2A-mCherry and NANOG nuclear intensity expression in untreated or Dox-treated cells in 2i+LIF after immunostaining experiments. The circles show the mean fluorescence for individual cells. Data for 24, 48, and 72h Dox treatment was pooled since they behaved similarly.

We next evaluated the effect of Oct6 expression in ground state conditions. While dox untreated cells formed typical compact dome-shaped colonies, the addition of Dox for 72h induced a pronounced morphological change similar to the observed upon differentiation, with flattened colonies, diminished cellcell interactions, and the formation of cellular protrusions (see Fig.2B). These changes could be observed as early as 24h after Dox treatment. As an additional control, no morphological changes were observed when using an inducible cell line that only overexpressed mCherry (Fig. S5A). Gene expression analysis showed that induction of Oct6 expression in 2i+LIF media upregulated the formative marker genes Sox3, Dnmt3A, Fgf5, Foxp1, Brn2, Zic2, Zic3, and endogenous Oct6, while not affecting Otx2 nor the general pluripotency marker Oct4 (Fig.2E, Fig. S5B). Of the formative marker genes, only Dnmt3A lacks OCT6-binding peaks in EpiSCs, suggesting that the remaining genes could be direct targets of Oct6 (see Fig. S4B). Importantly, no significant changes were observed in the expression of the nave pluripotency markers Esrrb, Rex1, Prdm14, Klf4, and Tbx3.

To gain a deeper insight into the regulatory effect of Oct6, we performed quantitative immunofluorescence experiments against key TFs regulated in this transition. OCT4, SOX2, and KLF4 showed similar protein levels between Dox treated and untreated mESCs, with only a slight reduction in the mean expression (Fig. S5C). In the case of SOX3, consistent with the gene expression data, we detected an important upregulation in a subset of OCT6 overexpressing cells, further reinforcing the regulatory link between these genes. We were particularly interested in the analysis of Nanog, not only because of its increased transcript levels in KO versus WT EpiLCs, but also because we discovered that NANOG and OCT6 proteins are expressed in a mutually exclusive manner in WT EpiLCs (Fig. S6A). Strikingly, while more than 90% of untreated cells expressed high levels of NANOG, we observed that overexpression of OCT6 repressed the expression of NANOG at the protein level in more than 70% of the cells, both at 24, 48 and 72h of Dox (Fig.2F, Fig. S6B). This effect was positively correlated with OCT6 levels and displayed a bistable switch-like behavior (Fig.2G). As a result, cells that were mCherry negative were more than 80% NANOG positive, while mCherry expression two-fold above background levels already showed more than 40% NANOG negative cells, suggesting that mild OCT6 expression is sufficient to repress NANOG (Fig.2H). For cells expressing mCherry at levels beyond four-fold above background, more than 90% of cells were NANOG negative. Interestingly, the fact that NANOG exhibited a clear bistabe ONOFF expression might indicate the existence of a repressive feedback loop between these TFs.

We next wondered whether the repression of NANOG was reversible after releasing the induction of OCT6. To answer this, we removed Dox from OCT6-induced cultures and analyzed mCherry and NANOG protein levels at different time points after washing the cells (Fig. S7A). Interestingly, as early as 24h after Dox removal, mCherry fluorescence returned to background levels and NANOG expression was restored (Fig. S7B). We did not observe appreciable differences in the levels of apoptosis among the experimental conditions, indicating that NANOG+/OCT6- derived from previously NANOG-/OCT6+cells (Fig. S8). The morphological changes induced by Dox were also reverted and colonies re-acquired their typical highly packed dome shape. Overall, these results indicate that OCT6 expression in nave culture conditions induces a reversible non-physiological identity with similarities to the formative pluripotent state.

To further analyze the dose dependency of OCT6 in NANOG repression, we took advantage of the expression of mCherry and analyzed 24h Dox-treated cells by flow cytometry, gating them into 3 populations, Low, Med, and High, all of them with the same number of cells (Fig.3A). In agreement with our previous results,~75% of cells in the mCherry-low population displayed high NANOG levels, while these percentages decreased to~35% and~2% in the mCherry-Med and mCherry-High populations, respectively (Fig.3B). By sorting these 3 cell populations, we confirmed the correlation between mCherry fluorescence and the mRNA levels of Oct6, mCherry, and the endogenous Sox3 mRNAs (Fig.3C). Interestingly, mCherry expression showed an inverse relation with Nanog mRNA levels, suggesting that OCT6 repressed Nanog at the transcriptional level. Even though the mCherry-Med population contained 65% of cells with reduced NANOG protein levels, we only observed a roughly two-fold reduction in its mRNA levels. This could be explained by the contribution of the remaining~35% fully NANOG positive cells, which can mask the downregulation when analyzing the mean Nanog mRNAs levels in the entire population. To complement these findings, we conducted a luciferase reporter assay to assess the impact of OCT6 expression on the Nanog promoter. Remarkably, induction of Oct6 using Dox resulted in a significant decrease in Nanog reporter activity, observed in both undifferentiated and 24h differentiating cells (Fig. S9A). These findings provide compelling evidence of OCT6's regulatory influence on the Nanog promoter, further supporting the notion of regulation at the transcriptional level. To reinforce these results, we performed single-molecule RNA-FISH experiments to detect individual Nanog mRNAs in OCT6 overexpressing cells. We first validated this method by analyzing undifferentiated mESCs and 24h EpiLCs, which confirmed homogeneous expression of Nanog transcripts in nave cells and a significant reduction as cells transited towards the formative state (Fig. S9B). After this validation, we evaluated the distribution of Nanog transcripts in undifferentiated cells induced to express Oct6 while simultaneously detecting NANOG and OCT6 proteins. As expected, cells with low levels of OCT6 protein were positive for Nanog transcripts and expressed NANOG at the protein level. Interestingly, cells with high levels of OCT6 protein did not present neither NANOG protein nor Nanog mRNAs (Fig.3D). In summary, our results demonstrate that OCT6 expression in nave ground state conditions represses Nanog at the transcriptional level. Together with the over-expression of formative-specific transcription factors such as Sox3 and the de novo DNA methyltransferase Dnmt3A, Oct6 might ultimately induce a shift in the nave GRN that partially sets it to a formative configuration similar to the early post-implantation epiblast.

Oct6 represses Nanog at the transcriptional level. (A) Flow cytometry sorting of 24h Dox treated cells into populations with low, medium (med), and high levels of mCherry. (B) Left. Correlation between mCherry and NANOG by flow cytometry. The different mCherry expressing subpopulations are shown. Right. The proportion of NANOG high, med, and low in the different mCherry expressing subpopulations. (C) RT-qPCR analysis of exogenous Oct6, mCherry, Sox3, and Nanog in Oct6 overexpressing cells. Untreated or Dox-treated cells (bulk population) are shown in black and statistically compared using a students t-test. The different mCherry expressing subpopulations are shown in shades of red and were compared using random block ANOVA. Different letters indicate significant differences (p<0.05). (D) Simultaneous single-molecule RNA FISH against Nanog cytoplasmic transcripts and immunostaining against Nanog and Oct6 proteins. The insets show example cells with high and low Oct6 transgene expression. Scale bar: 20m.

Our results so far demonstrated that OCT6 and NANOG are expressed in a mutually exclusive manner in WT EpiLCs and that OCT6 activates its own transcription while repressing the expression of Nanog. Moreover, Nanog is known to present positive autoregulation26,27. This led us to hypothesize that these two TFs could constitute a double negative feedback loop that could act as a toggle switch to initiate the dissolution of the nave pluripotent state. Indeed, we have previously shown that NANOG binds to CRE#2 in Oct6s promoter along with OCT4, OTX2 and ESRRB (see Fig. S2). To assess if OCT6 might also bind to the Nanog locus, we analyzed the aforementioned work by Matsuda et al. in EpiSCs. While the ChIP-seq signal in Nanog locus exhibited relatively low intensity, we observed a discrete accumulation of reads at the 5kb distal enhancer located upstream of the Nanog TSS (Fig. S9C). This distal enhancer, recognized as a crucial CRE, is known to be targeted by other key pluripotency transcription factors28,29. This subtle observation prompted us to consider that OCT6 might bind to Nanogs promoter in EpiLCs.

Finally, we evaluated if NANOG inhibited the expression of Oct6 by generating a cell line capable of expressing a Nanog transgene under the control of Dox (Fig.4A). As in the case of Oct6 overexpression, this cell line also expresses mCherry via a self-cleaving peptide. To confirm the correct behavior of this line, we first differentiated them for 48h in the presence or absence of Dox and confirmed that they expressed mCherry and NANOG in a highly correlated fashion (Fig.4B,C). Next, we evaluated whether Dox-treated EpiLCs showed reduced levels of OCT6. Our results show that while mCherry negative cells exhibited normal levels of OCT6, mCherry expressing cells did not express this transcription factor, indicating that NANOG repressed Oct6 in a cell-autonomous fashion (Fig.4D,E). Overall, our results indicate that these genes could constitute a toggle-switch circuit important for the correct dissolution of nave pluripotency and the transition to a post-implantation epiblast-like phenotype.

Oct6 and Nanog repress each other forming a double negative feedforward loop network motive. (A) Diagram of the Nanog-P2A-mCherry overexpressing construct and the experimental design. (B) Treatment with Dox during EpiLC differentiation induces the expression of mCherry. Scale bar: 50m. (C) The plot shows the correlation of mean nuclear intensity fluorescence of mCherry and NANOG obtained from NAONG immunostaining of Dox-treated EpiLCs. Each circle shows the data of one individual nucleus. (D) Immunostaining of OCT6 showing that Dox-treated Nanog-P2A-mCherry overexpressing cells do not express OCT6. Conversely, Dox-treated cells not expressing Nanog-P2A-mCherry normally express OCT6. Scale bar: 50m. (E) The plot shows the correlation of mean nuclear intensity fluorescence of Nanog-P2A-mCherry and OCT6, obtained from OCT6 immunostaining of Dox-treated EpiLCs. Each circle shows the data of one individual nucleus. (F) Proposed model of transcriptional circuitry between Nanog and Oct6 that regulates the transition from nave to formative pluripotency.

See more here:
The transcription factor OCT6 promotes the dissolution of the nave pluripotent state by repressing Nanog and ... - Nature.com

Stem Cell and Platelet Rich Plasma Alopecia Therapies Market Analysis and Future Outlook by 2030 – openPR

The global stem cell and platelet rich plasma alopecia therapies market is expected to grow at a significant CAGR during the forecast period. Increased need for accurate and rapid alopecia treatment, as well as breakthroughs in platelet rich plasma and stem cell therapies that have transformed diagnostic technology, which is expected to drive the market forward. Furthermore, the global market is likely to be driven by an increase in awareness of platelet rich plasma therapies and stem cell therapies over the forecast period.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/stem-cell-and-platelet-rich-plasma-alopecia-therapies-market

In the last few years, increased awareness has fueled demand for platelet rich plasma therapy and stem cell therapy in developing countries like Japan, India, Brazil, and Russia, as well as developed regions like North America and Europe. Furthermore, private actors are actively marketing the benefits of stem cell therapy in the treatment of alopecia around the globe. The global stem cell and platelet rich plasma alopecia therapies market is expected to grow as the incidence of autoimmune hair loss disorders such as alopecia rises. However, the global market for stem cell and platelet rich plasma alopecia therapies is anticipated to be hampered by a lack of therapy approval and the high cost of alopecia treatment.

The global market has been divided into platelet rich plasma therapies and stem cell therapy based on treatment. Owing to the therapies' efficiency in the treatment of several forms of alopecia, the platelet rich plasma therapies sector had a substantial market share. Platelet-rich plasma therapies have changed alopecia treatment by lowering expenses, lengthening treatment times, and speeding up recovery time for patients. The bone marrow and adipose stem cell treatment segments have been separated.

Global Stem Cell and Platelet Rich Plasma Alopecia Therapies Market by Segments

By Treatment

Platelet Rich Plasma Therapies Stem Cell Therapy

By End-User

Hospitals Dermatology Clinics Others

A full report of Stem Cell and Platelet Rich Plasma Alopecia Therapies Market is available at: https://www.omrglobal.com/industry-reports/stem-cell-and-platelet-rich-plasma-alopecia-therapies-market

Stem Cell and Platelet Rich Plasma Alopecia Therapies Market- Segment by Region

North America

United States Canada

Europe

Germany United Kingdom France Spain Italy Rest of Europe

Asia-Pacific

China Japan India Rest of Asia-Pacific

Rest of the World

Middle East & Africa Latin America

Company Profiles

Stemcell technologies Inc. Myungmoon Bio Co., Ltd. RepliCel Life Sciences Histogen, Inc. Glofinn Oy.

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors. 2. More than 120 countries are for analysis. 3. Over 100+ paid data sources mined for investigation. 4. Our expert research analysts answer all your questions before and after purchasing your report.

Visit more report at

https://www.linkedin.com/pulse/scaffold-technology-market-size-trends-latest-arti-vishwakarma-mlsof/

https://www.linkedin.com/pulse/aesthetic-threads-market-increasing-demand-growth-2031-vishwakarma-pyg5f

Media Contact:

Contact Person: Mr. Anurag Tiwari Email: anurag@omrglobal.com Contact no: +91 780-304-0404 Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.

Go here to read the rest:
Stem Cell and Platelet Rich Plasma Alopecia Therapies Market Analysis and Future Outlook by 2030 - openPR

Clinic offers revolutionary gene therapies for blood disorders – Daily Guardian

Dr. Rabi Hanna

Ahead of World Thalassemia Day on May 8, Cleveland Clinic has announced the availability of groundbreaking gene therapies for sickle cell disease and beta thalassemia, offering new hope for individuals suffering from these severe inherited blood disorders.

The main campus has become one of the few centers globally authorized to administer these novel treatments that have shown potential to functionally cure these conditions.

Sickle cell disease and beta thalassemia affect the bodys ability to produce or process hemoglobin, the protein responsible for oxygen transport in the blood. These disorders can lead to severe health complications and significantly reduce life expectancy.

Traditionally, treatment has been limited to symptom management through blood transfusions and medication, which can lead to further complications such as iron overload and organ damage.

Dr. Rabi Hanna, a hematologist-oncologist and director of the pediatric blood and bone marrow transplant program at Cleveland Clinic Childrens, described the therapies as well-tolerated and transformative. He explained, These new therapies could enable individuals to live free from the often-debilitating effects of these diseases.

The therapies involve extracting a patients own blood-producing stem cells, modifying them to produce functionally normal red blood cells, and then reintroducing them to the patients body. This process eliminates the need for a donor match and reduces the risks associated with traditional transplant procedures, such as immune rejection and graft-versus-host disease (GVHD).

Among the therapies offered, exagamglogene autotemcel [Casgevy] is notable for being the first U.S.-approved treatment using the CRISPR gene-editing technology, which won the Nobel Prize in chemistry in 2020. This therapy is applicable to both sickle cell disease and beta thalassemia in individuals aged 12 and older, including adults. Other therapies available include lovotibeglogene autotemcel [Lyfgenia] for sickle cell disease and betibeglogene autotemcel [Zynteglo] for transfusion-dependent beta thalassemia.

Dr. Hanna highlighted the extensive preparation involved in these treatments. This is a treatment journey involving several phases, he said, noting that international patients can undergo preliminary phases in their own countries before completing the treatment at Cleveland Clinic.

The entire process involves initial body preparation, stem cell collection and modification, followed by chemotherapy and a hospital stay of four to six weeks to ensure successful engraftment of the modified cells.

Cleveland Clinics Global Patient Services (GPS) department is instrumental in assisting international patients with medical appointments and travel arrangements, ensuring a smooth treatment process.

These therapies represent a significant advancement in the treatment of hemoglobin disorders, which affect millions globally. According to the World Health Organization, about 5% of the worlds population carries trait genes for these disorders, with approximately 300,000 babies born with severe conditions each year.

Read more here:
Clinic offers revolutionary gene therapies for blood disorders - Daily Guardian